1. Clinicians' Corner in Dyslipidemia

3. Multiple Challenges With Statin Selection

4. Statin-Associated Muscle Symptoms vs Statin Intolerance

5. GAUSS 3 Study Design

6. GAUSS 3 Study Implications

7. Nonstatin Therapy for Adjunct LDL-Lowering

8. PCSK9 Inhibitors Dosing and Administration

9. PCSK9 Inhibitors Indications

10. FOURIER Trial Design

11. Summary of Effects of PCSK9I Evolocumab

12. FOURIER Trial: Relationship Between Achieved LDL-c Levels at One Month to Measures of Benefit

13. FOURIER Safety

14. Nonstatin Recommendations From Treatment Guidelines

15. Guideline Recommendations for Additional LDL-C Reduction With Nonstatin Therapy

16. When to Consider Nonstatin Therapy

17. Alirocumab ODYSSEY Outcomes Trial

18. Alirocumab ODYSSEY Outcomes Trial Results

19. Navigating the Prior Authorization Process Clinical Pearls

20. Statin-Associated Myopathy Risk Factors

21. Successful Statin Reintroduction

22. Management of Statin-Related AEs

23. Sample Uniform Prior Authorization and Appeals Letters

24. Improving PCSK9 Inhibitor Approval Rates

25. Real-World Experience With FH and PCSK9 Inhibitors

26. Navigating the Prior Authorization Process With the Patient

27. Clinical Management of the Patient With Dyslipidemia

28. Specialty Pharmacy PCSK9 Inhibitor Access

29. Clinical Tips for Therapeutic Management of PCSK9 Inhibitors

30. Conclusion

31. Abbreviations

32. Abbreviations (cont)